Epstein Files Full PDF

CLICK HERE
Technopedia Center
PMB University Brochure
Faculty of Engineering and Computer Science
S1 Informatics S1 Information Systems S1 Information Technology S1 Computer Engineering S1 Electrical Engineering S1 Civil Engineering

faculty of Economics and Business
S1 Management S1 Accountancy

Faculty of Letters and Educational Sciences
S1 English literature S1 English language education S1 Mathematics education S1 Sports Education
teknopedia

  • Registerasi
  • Brosur UTI
  • Kip Scholarship Information
  • Performance
Flag Counter
  1. World Encyclopedia
  2. Azapride - Wikipedia
Azapride - Wikipedia
From Wikipedia, the free encyclopedia
Chemical compound
Pharmaceutical compound
Azapride
Clinical data
Other namesAzidoclebopride
ATC code
  • None
Identifiers
IUPAC name
  • 4-Azido-5-chloro-2-methoxy-N-[1-(phenylmethyl)piperidin-4-yl]benzamide
CAS Number
  • 92990-90-4 checkY
PubChem CID
  • 3036441
ChemSpider
  • 2300456 checkY
UNII
  • URS8YWT9Q7
CompTox Dashboard (EPA)
  • DTXSID00239217 Edit this at Wikidata
Chemical and physical data
FormulaC20H22ClN5O2
Molar mass399.88 g·mol−1
3D model (JSmol)
  • Interactive image
SMILES
  • Clc1cc(c(OC)cc1/N=[N+]=[N-])C(=O)NC3CCN(Cc2ccccc2)CC3
InChI
  • InChI=1S/C20H22ClN5O2/c1-28-19-12-18(24-25-22)17(21)11-16(19)20(27)23-15-7-9-26(10-8-15)13-14-5-3-2-4-6-14/h2-6,11-12,15H,7-10,13H2,1H3,(H,23,27) checkY
  • Key:CKKHIIXHAWWTNP-UHFFFAOYSA-N checkY
  (verify)

Azapride is the azide derivative of the dopamine antagonist clebopride synthesized in order to label dopamine receptors.[1][2] It is an irreversible dopamine antagonist.[2]

References

[edit]
  1. ^ Niznik HB, Guan JH, Neumeyer JL, Seeman P (February 1985). "A photoaffinity ligand for dopamine D2 receptors: azidoclebopride". Molecular Pharmacology. 27 (2): 193–9. doi:10.1016/S0026-895X(25)12275-X. PMID 3969068.
  2. ^ a b Wouters W, Van Dun J, Laduron PM (December 1984). "Photoaffinity labelling of dopamine receptors. Synthesis and binding characteristics of azapride". European Journal of Biochemistry. 145 (2): 273–8. doi:10.1111/j.1432-1033.1984.tb08548.x. PMID 6548707.
  • v
  • t
  • e
Dopamine receptor modulators
D1-like
Agonists
  • Benzazepines: 6-Br-APB
  • Fenoldopam
  • SKF-38,393
  • SKF-77,434
  • SKF-81,297
  • SKF-82,958
  • SKF-83,959
  • Trepipam
  • Zelandopam
  • Ergolines: Cabergoline
  • CY-208,243
  • Dihydroergocryptine
  • LEK-8829
  • Lisuride
  • Pergolide
  • Terguride
  • Dihydrexidine derivatives: A-77636
  • A-86929
  • Adrogolide (ABT-431, DAS-431)
  • Dihydrexidine
  • Dinapsoline
  • Dinoxyline
  • Doxanthrine
  • Phenethylamines: BCO-001
  • Deoxyepinephrine (N-methyldopamine, epinine)
  • Dipropyldopamine (DPDA)
  • Dopamine
  • Dopexamine
  • Etilevodopa
  • Ibopamine
  • L-DOPA (levodopa)
  • Lu AE04621
  • Melevodopa
  • L-Phenylalanine
  • L-Tyrosine
  • XP21279
  • Others: A-68930
  • Apomorphine
  • Isocorypalmine
  • Lu AF28996
  • Nuciferine
  • PF-06412562
  • PF-6649751
  • PF 6669571
  • Propylnorapomorphine
  • Rotigotine
  • SKF-89,145
  • SKF-89,626
  • Stepholidine
  • Tavapadon
  • Tetrahydropalmatine
PAMs
  • Tetrahydroisoquinolines: DETQ
  • DPTQ
  • Glovadalen
  • Mevidalen
Antagonists
  • Typical antipsychotics: Butaclamol
  • Chlorpromazine
  • Chlorprothixene
  • Flupentixol (flupenthixol) (+melitracen)
  • Fluphenazine
  • Loxapine
  • Perphenazine (+amitriptyline)
  • Pifluthixol
  • Thioridazine
  • Thiothixene
  • Trifluoperazine (+tranylcypromine)
  • Zuclopenthixol
  • Atypical antipsychotics: Asenapine
  • Clorotepine
  • Clotiapine
  • Clozapine
  • DHA-clozapine
  • Fluperlapine
  • Iloperidone
  • Norclozapine
  • Norquetiapine
  • Olanzapine (+fluoxetine)
  • Paliperidone
  • Quetiapine
  • Risperidone
  • Tefludazine
  • Zicronapine
  • Ziprasidone
  • Zotepine
  • Others: Berupipam
  • Ecopipam
  • EEDQ
  • Metitepine (methiothepin)
  • Odapipam
  • Perlapine
  • SCH-23390
D2-like
Agonists
  • Adamantanes: Amantadine
  • Memantine
  • Rimantadine
  • Aminotetralins: 5-OH-DPAT
  • 7-OH-DPAT
  • 8-OH-PBZI
  • CHF-1024
  • Nolomirole
  • Rotigotine
  • UH-232
  • Ergolines: Bromocriptine
  • Cabergoline
  • Chanoclavine
  • Dihydroergocryptine
  • Disulergine
  • Dosergoside
  • Epicriptine
  • Ergocornine
  • Etisulergine
  • Lergotrile
  • Lisuride
  • LSD
  • Mesulergine
  • Metergoline
  • Pergolide
  • Proterguride
  • Terguride
  • Dihydrexidine derivatives: 2-OH-NPA
  • Ciladopa
  • Dihydrexidine
  • Dinoxyline
  • N,N-Propyldihydrexidine
  • Phenethylamines: Deoxyepinephrine (N-methyldopamine, epinine)
  • Dipropyldopamine (DPDA)
  • Dopamine
  • Dopexamine
  • Etilevodopa
  • Ibopamine
  • L-DOPA (levodopa)
  • Lu AE04621
  • L-Phenylalanine
  • RU-24213
  • L-Tyrosine
  • Melevodopa
  • XP21279
  • Atypical antipsychotics: Alentemol (U-66444B)
  • Aripiprazole (+sertraline)
  • Aripiprazole lauroxil
  • Bifeprunox
  • Brexpiprazole
  • Brilaroxazine
  • Cariprazine
  • F-15063
  • Lumateperone
  • Norclozapine
  • Others: 3-PPP
  • A-412997
  • ABT-670
  • ABT-724
  • Adrafinil
  • Aplindore
  • Apomorphine
  • Arketamine
  • Armodafinil
  • BP-897
  • Captodiame
  • CP-226,269
  • Debenzergoline
  • Dizocilpine
  • Esketamine
  • Etrabamine
  • Flibanserin
  • 7-Hydroxyropinirole (SK&F-89124)
  • Ketamine
  • Lu AF28996
  • Matsupexole
  • Modafinil
  • Naxagolide
  • OSU-6162
  • Pardoprunox
  • PD-128,907
  • PD-168,077
  • PF-219,061
  • PF-592,379
  • Phencyclidine
  • Piribedil
  • Pramipexole
  • Preclamol
  • Propylnorapomorphine
  • Pukateine
  • Quinagolide
  • Quinelorane
  • Quinpirole
  • RDS-127
  • Ro10-5824
  • Ropinirole
  • Roxindole
  • S32504
  • Salvinorin A
  • SKF-39315
  • SKF-83,959
  • Sumanirole
  • Talipexole
  • Umespirone
  • WAY-100,635
  • XC-130
Antagonists
  • Typical antipsychotics: Acepromazine
  • Acetophenazine
  • Azaperone
  • Benperidol
  • Bromperidol
  • Butaclamol
  • Butaperazine
  • Chloracizine
  • Chlorproethazine
  • Chlorpromazine
  • Chlorprothixene
  • Ciclindole
  • Clopenthixol
  • Clothixamide
  • Clopimozide
  • Droperidol
  • Fluacizine
  • Fluanisone
  • Flucindole
  • Fluotracen
  • Flupentixol (flupenthixol) (+melitracen)
  • Fluphenazine
  • Fluprothixene
  • Fluspirilene
  • Haloperidol
  • Homopipramol
  • Lenperone
  • Levomepromazine (methotrimeprazine)
  • Levosulpiride
  • Loxapine
  • Mesoridazine
  • Moperone
  • Naranol
  • Nemonapride
  • Penfluridol
  • Perathiepin
  • Perazine
  • Pericyazine (periciazine)
  • Perphenazine (+amitriptyline)
  • Piflutixol (pifluthixol)
  • Pimozide
  • Pipamperone
  • Preclamol
  • Prochlorperazine
  • Promazine
  • Prothipendyl
  • Spiperone (spiroperidol)
  • Sulforidazine
  • Sulpiride
  • Sultopride
  • Teflutixol
  • Thiopropazate
  • Thioproperazine
  • Thioridazine
  • Thiothixene
  • Timiperone
  • Trifluoperazine (+tranylcypromine)
  • Triflupromazine
  • Trifluperidol
  • Zetidoline
  • Zuclopenthixol
  • Atypical antipsychotics: Amisulpride
  • Asenapine
  • BL-1020
  • Blonanserin
  • Carpipramine
  • Cinuperone
  • Clocapramine
  • Clorotepine
  • Clotiapine (clothiapine)
  • Clozapine
  • Cyamemazine
  • DHA-clozapine
  • Dixyrazine
  • Elopiprazole
  • Flumezapine
  • Fluperlapine
  • Gevotroline
  • Iloperidone
  • Lurasidone
  • Mazapertine
  • Melperone
  • Molindone
  • Mosapramine
  • Ocaperidone
  • Olanzapine (+fluoxetine)
  • Paliperidone
  • Perospirone
  • Piperacetazine
  • Pipotiazine
  • Piquindone
  • Quetiapine
  • Remoxipride
  • Risperidone
  • Sertindole
  • Tefludazine
  • Tenilapine
  • Tiospirone
  • Veralipride
  • Zicronapine
  • Ziprasidone
  • Zotepine
  • Antiemetics/gastroprokinetics/sedatives: Aceprometazine
  • AS-8112
  • Alimemazine
  • Alizapride
  • Benzquinamide
  • Bromopride
  • Clebopride
  • Deudomperidone
  • Domperidone
  • Eticlopride
  • Hydroxyzine
  • Itopride
  • Metoclopramide
  • Metopimazine
  • Promethazine
  • Thiethylperazine
  • Trazpiroben
  • Trimethobenzamide
  • Antidepressants: Amoxapine
  • Nefazodone
  • Opipramol
  • Propiomazine
  • Trimipramine
  • Others: 3-PPP
  • Alpiropride
  • Azapride
  • Bromerguride
  • Bromocriptine
  • Buspirone
  • Carmoxirole
  • Desmethoxyfallypride
  • EEDQ
  • F-15063
  • Fallypride
  • Fananserin
  • Fenfluramine
  • Iodobenzamide
  • Isocorypalmine
  • L-741,626
  • L-745,870
  • Levofenfluramine
  • LEK-8829
  • Metitepine (methiothepin)
  • N-Methylspiperone
  • Nafadotride
  • Nuciferine
  • Ordopidine
  • PNU-99,194
  • Pridopidine
  • Raclopride
  • Sarizotan
  • SB-277,011-A
  • Seridopidine
  • Sonepiprazole
  • Spiroxatrine
  • Stepholidine
  • SV-293
  • Tetrahydropalmatine
  • Tiapride
  • UH-232
  • XC-130
  • Yohimbine
  • See also: Receptor/signaling modulators
  • Adrenergics
  • Serotonergics
  • Monoamine reuptake inhibitors
  • Monoamine releasing agents
  • Monoamine metabolism modulators
  • Monoamine neurotoxins
Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by adding missing information.

  • v
  • t
  • e
Retrieved from "https://teknopedia.ac.id/w/index.php?title=Azapride&oldid=1329511907"
Categories:
  • Drugs not assigned an ATC code
  • Dopamine antagonists
  • Organoazides
  • Chlorobenzene derivatives
  • Salicylamide ethers
  • Piperidines
  • Irreversible antagonists
  • Nervous system drug stubs
Hidden categories:
  • Articles with short description
  • Short description matches Wikidata
  • Short description is different from Wikidata
  • Articles without EBI source
  • Chemical pages without DrugBank identifier
  • Articles without KEGG source
  • Drugs with no legal status
  • All stub articles

  • indonesia
  • Polski
  • العربية
  • Deutsch
  • English
  • Español
  • Français
  • Italiano
  • مصرى
  • Nederlands
  • 日本語
  • Português
  • Sinugboanong Binisaya
  • Svenska
  • Українська
  • Tiếng Việt
  • Winaray
  • 中文
  • Русский
Sunting pranala
url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url
Pusat Layanan

UNIVERSITAS TEKNOKRAT INDONESIA | ASEAN's Best Private University
Jl. ZA. Pagar Alam No.9 -11, Labuhan Ratu, Kec. Kedaton, Kota Bandar Lampung, Lampung 35132
Phone: (0721) 702022
Email: pmb@teknokrat.ac.id